Addressing urgent unmet needs in rare diseases
At Hansa Biopharma, we are on a mission to develop innovative immunomodulatory treatments and bring them to those patients whose medical needs have been overlooked.
This is HansaYears of innovation
Clinical and preclinical programs
Nationalities represented in our workforce
Annual Report 2022
Sustainability Report 2022
Our Technology platform
We have developed our proprietary antibody-cleaving enzyme technology platform to target pathogenic or disease causing antibodies. Our first-generation IgG-cleaving enzyme, imlifidase, is designed to inactivate IgG antibodies in the plasma and tissue through a single intravenous treatment. We are currently investigating the use of this molecule for treating and preventing rare conditions caused by IgG antibodies in the acute phase, within transplantation, autoimmunity, gene therapy and oncology.
Hansa story
At Hansa, our ambition is to help empower patients with rare immunological conditions to live long and healthy lives. By developing innovative, lifesaving and life altering treatments and bringing them from the laboratory to the bedside of the patient, we strive to help address their unmet medical need.
Media
Regulatory press release
01/09/2023
Regulatory press release
31/07/2023
Regulatory press release
20/07/2023
19/07/2023
Our unique enzyme technology has the potential to transform the lives of people affected by rare immunologic conditions, including transplant rejection, genetic diseases, autoimmune conditions, and cancer.
Melissa. Highly sensitized kidney patient on dialysis, USA.
Since 2007, we have been fully committed to those living with rare conditions and have worked to develop lifesaving and life altering therapies through pioneering research and innovation. We strive to live up to the high ethical standards we set for ourselves, and to be a force for good both for individuals and society as a whole.
Our commitmentMedia
Our strong company culture is what led us to be awarded Great Place to Work for four consecutive years from 2020 to 2023, by the independent institute Great Place to Work®, a global authority on workplace culture, employee experience and leadership behavior. In addition, Hansa has been selected among the best workplaces in Sweden in 2023.